Featured News

The Celiac Disease Foundation is pleased to announce it will provide patient recruitment and eligibility screening for Anokion’s phase 1b/2 clinical trial for KAN-101.

The PROACTIVE Celiac Study is a phase 2 clinical trial testing the safety and effects of the investigational medication PRV-015.

Consider joining the LILY Study, a phase 1 clinical trial for people with celiac disease investigating DONQ52, a new potential celiac disease treatment.

New research studying the association of celiac disease and inflammatory bowel disease (IBD) shows a strong relationship between the two conditions.

On July 27, Celiac Disease Foundation CEO, Marilyn G. Geller, will be presenting the “Role of Patient Advocacy in Clinical Trials” on a webinar hosted by the Society for the Study of Celiac Disease.

An analysis by an independent statistician of the ongoing Phase 3 trial for Larazotide has concluded that a substantial number of new patients would have to be added to the existing trial in order to get scientifically meaningful results.

According to a recent analysis, children who have a first-degree relative with celiac disease may be at higher risk of developing the disease before age 10 than previously thought.

The Celiac Disease Foundation was honored to award the first annual Prize for Excellence in Celiac Disease Research to Dr. Joseph Murray. The Foundation was also honored to award the first annual Young Investigator Prize to Dr. Jocelyn Silvester.

Anokion SA released successful results from their Phase 1 ACeD clinical trial and they will be moving forward with Phase 2 trials later this year.

This educational event is the second in a series of 10 bimonthly programs and is open to healthcare professionals and patients. Registration is required and free to all registrants.